Your browser doesn't support javascript.
loading
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
Gerds, Aaron T; Tauchi, Tetsuzo; Ritchie, Ellen; Deininger, Michael; Jamieson, Catriona; Mesa, Ruben; Heaney, Mark; Komatsu, Norio; Minami, Hironobu; Su, Yun; Shaik, Naveed; Zhang, Xiaoxi; DiRienzo, Christine; Zeremski, Mirjana; Chan, Geoffrey; Talpaz, Moshe.
Afiliação
  • Gerds AT; Leukemia and Myeloid Disorders Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Electronic address: gerds@ccf.org.
  • Tauchi T; Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan. Electronic address: tauchi@tokyomed.ac.jp.
  • Ritchie E; Weill Cornell Medical College of Cornell University, 1300 York Ave, New York, NY 10065, USA. Electronic address: ritchie@med.cornell.edu.
  • Deininger M; Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr, Salt Lake City, UT 84112, USA. Electronic address: michael.deininger@hci.utah.edu.
  • Jamieson C; Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Dr, La Jolla, CA 92093, USA. Electronic address: cjamieson@ucsd.edu.
  • Mesa R; UT Health San Antonio Cancer Center, 7979 Wurzbach Rd, San Antonio, TX 78229, USA. Electronic address: mesar@uthscsa.edu.
  • Heaney M; Columbia University Medical Center, 630 West 168th St, New York, NY 10032, USA. Electronic address: mlh2192@cumc.columbia.edu.
  • Komatsu N; Juntendo University School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Electronic address: komatsun@juntendo.ac.jp.
  • Minami H; Division of Medical Oncology /Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. Electronic address: hminami@med.kobe-u.ac.jp.
  • Su Y; Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA. Electronic address: yun_su@msn.edu.
  • Shaik N; Pfizer Inc, 10555 Science Center Drive, San Diego, CA, 92121 USA. Electronic address: naveed.shaik@pfizer.com.
  • Zhang X; Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA. Electronic address: xiaoxi.zhang@pfizer.com.
  • DiRienzo C; Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA. Electronic address: christine.d.dirienzo@pfizer.com.
  • Zeremski M; Pfizer Inc, 10555 Science Center Drive, San Diego, CA, 92121, United States. Electronic address: mirjana.zeremski@pfizer.com.
  • Chan G; Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA. Electronic address: geoffrey.chan@pfizer.com.
  • Talpaz M; Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Dr, Ann Arbor, MI 48109, USA. Electronic address: mtalpaz@med.umich.edu.
Leuk Res ; 79: 38-44, 2019 04.
Article em En | MEDLINE | ID: mdl-30849661
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Pirazóis / Benzimidazóis / Mielofibrose Primária Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Pirazóis / Benzimidazóis / Mielofibrose Primária Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leuk Res Ano de publicação: 2019 Tipo de documento: Article